Prospective Observational Study of Systemic Therapy for HCC in Japan: Exploratory Biomarker-Analysis

Multicenter Observational Study to Evaluate Factors Related to Angiogenesis and Tumor Immunity in Unresectable Hepatocellular Carcinoma - PRISM-Bio Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048298

Enrollment

300

Registered

2022-07-15

Start date

2022-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled in PRISM Study with written informed consent for PRISM-Bio Study.

Exclusion criteria

Exclusion criteria: No particular setting

Design outcomes

Primary

Measure	Time frame
To analyze some biomarkers of angiogenesis-related and tumor-immunity-related factors serially and to clarify the relationship of the biomarker with patient background, clinicopathological findings, treatment response (overall survival, progression-free survival, objective response rate, etc.), and adverse events.	—

Countries

Japan

Contacts

Public ContactShinji Itoh

Kyushu University Department of surgery and science, Graduate school of medical science

itoh.shinji.453@m.kyushu-u.ac.jp092-642-5466

Outcome results